Pancreatic Cancer Research

ResearcherSichuan UniversityActive in the last 2 years

Ke Cheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6034-8872; OpenAlex author ID A5014465282. Sources: OpenAlex.

Their work

Papers
14 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
44
Papers, trials and grants by year

2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: 2 papers · 2025: 3 papers · 2026: 2 papers

Papers 14

  1. Chinese expert consensus on precision testing and molecular diagnosis of pancreatic cancer (2025). Co-author DOI 10.1038/s41416-026-03522-x↗
  2. Radiotherapy combined with serplulimab, and chemotherapy as first-line treatment for metastatic pancreatic adenocarcinoma: a multicenter, single-arm, phase II … Co-author DOI 10.1158/1078-0432.ccr-26-1824↗
  3. PLEK2 promotes migration and invasion in pancreatic ductal adenocarcinoma by MMP1 through IL-17 pathway. Co-author DOI 10.1007/s11010-024-05078-x↗
  4. RETRACTED: Serplulimab combined with gemcitabine, nab-paclitaxel, and stereotactic body radiotherapy as first-line treatment for metastatic pancreatic adenocar… First author DOI 10.21203/rs.3.rs-7291840/v1↗
  5. Case Report: Combined PD-1 and tyrosine kinase blockade stabilizes refractory pancreatic cancer guided by the spatial structure of tumor immune microenvironmen… Co-author DOI 10.3389/fimmu.2025.1547388↗
  6. CDK4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-024-57417-z↗
  7. Serplulimab combined with gemcitabine, nab-paclitaxel and stereotactic body radiotherapy as the first-line treatment for patients with metastatic pancreatic ad… Co-author DOI 10.1136/bmjopen-2024-084274↗
  8. A Phase I Study of Gemcitabine/Nab-Paclitaxel/S-1 Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1093/oncolo/oyac146↗
  9. Stuttering as a signal of encephalopathy associated with toripalimab in a pancreatic ductal adenocarcinoma patient: a case report. Co-author DOI 10.1186/s12883-023-03140-7↗
  10. Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastatic pancreatic ductal adenocarcinoma: an o… First author DOI 10.21203/rs.3.rs-3677396/v1↗
  11. A Modified Regimen of 21-day Nab-Paclitaxel Plus Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer: A Retrospective Real-World Study. Co-author DOI 10.1177/10732748221141233↗
  12. Durable Response of Induction Sequential Chemotherapy Combined With Nimotuzumab and Consolidative Carbon Ion Radiotherapy With Non-V600 BRAF Mutation Locally A… Co-author DOI 10.21203/rs.3.rs-809969/v1↗
  13. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for … First author DOI 10.1186/s12885-020-07126-3↗
  14. Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Ad… First author DOI 10.3389/fimmu.2020.01127↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Dan Cao · 5 shared papers, 2023–2026 · strength 0.98
  2. Junjie Xiong · 5 shared papers, 2023–2026 · strength 0.89
  3. Chenyan Zhang · 4 shared papers, 2024–2026 · strength 0.85
  4. Chen Chang · 5 shared papers, 2021–2026 · strength 0.84
  5. Dan Cao · 5 shared papers, 2020–2023 · strength 0.76
  6. Yi Cheng · 5 shared papers, 2020–2026 · strength 0.75
  7. Qingqing Leng · 3 shared papers, 2025–2026 · strength 0.64
  8. Bing Peng · 3 shared papers, 2022–2025 · strength 0.58
  9. Wanrui Lv · 3 shared papers, 2023 · strength 0.56
  10. Zixing Huang · 3 shared papers, 2023–2026 · strength 0.50
  11. Qiangxing Chen · 2 shared papers, 2024–2025 · strength 0.42
  12. He Cai · 2 shared papers, 2024–2025 · strength 0.42
  13. Xin Wang · 2 shared papers, 2024–2025 · strength 0.42
  14. Huanji Xu · 2 shared papers, 2025–2026 · strength 0.39
  15. Xiaorui Zhu · 2 shared papers, 2025–2026 · strength 0.36
  16. Wanting Hou · 2 shared papers, 2025–2026 · strength 0.36
  17. Chengjian Zhao · 2 shared papers, 2023–2025 · strength 0.31
  18. Rui Wang · 2 shared papers, 2023–2025 · strength 0.31
  19. Heqi Yang · 1 shared paper, 2025 · strength 0.28
  20. Dan Cao · 1 shared paper, 2025 · strength 0.28
  21. Xi Chen · 1 shared paper, 2023 · strength 0.24
  22. Jianping He · 1 shared paper, 2023 · strength 0.24
  23. Lin Shui · 2 shared papers, 2020 · strength 0.23
  24. Wei Li · 1 shared paper, 2026 · strength 0.23
  25. Chunyi Hao · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.